SB 5988
SignedSenate
Opioid treatment prg. fees
Establishing fee authority for accreditation services provided to opioid treatment programs by the department of health.
How does a bill become law?
- Introduced: The bill is filed and assigned a number.
- Committee: A subject-matter committee holds hearings, takes public testimony, and decides whether to advance the bill.
- Floor Vote: The full chamber (House or Senate) debates and votes on the bill.
- Opposite Chamber: The bill repeats the committee and floor vote process in the other chamber.
- Governor: The Governor reviews the bill and decides whether to sign or veto it.
- Signed: The bill has been signed into law.
AI Analysis
This bill lets the Washington State Department of Health apply to become the official accreditor of opioid treatment programs in the state, and to charge fees to cover the costs of that work. If approved by the federal government, the Department would set fees and could use opioid settlement funds to help pay for the program.
- Authorizes the Department of Health to apply to the U.S. Department of Health and Human Services to become an approved accrediting body for opioid treatment programs under federal rules (42 C.F.R. Part 8).
- If approved, the Department must follow federal policies and procedures for accreditation and establish accreditation fees by rule.
- Requires that fees (including initial and renewal fees) be set at levels sufficient to cover the full cost of providing accreditation services.
- Allows the Department to use money from the opioid abatement settlement account to help pay for accreditation activities.
Who is affected
- Opioid treatment programs — Opioid treatment programs in Washington must pay fees to obtain or renew accreditation if the state becomes an approved accreditor; these fees help cover the cost of the accreditation process.
- Washington State Department of Health — The state agency will gain new authority to set and collect fees for accreditation services, and may use opioid settlement funds to help cover program costs.
- Residents using opioid treatment services — People receiving medication-assisted treatment for opioid use disorder may benefit from more consistent oversight if state-level accreditation improves program quality and access.
Pro/Con Analysis
Stronger case for benefits
Potential Benefits (3)
State-level accreditation may improve consistency, oversight, and quality of opioid treatment programs—potentially increasing access and safety for people with opioid use disorder, especially vulnerable populations who rely on publicly supported clinics.
HealthcarePeopleRef: Sec. 1(1), (2)(a), (4)Allowing use of opioid abatement settlement funds to offset accreditation costs helps ensure program sustainability without diverting funds from direct treatment or prevention services, and avoids placing full cost burden on state general fund or program operators.
HealthcarePeopleRef: Sec. 1(4)Standardized, state-administered accreditation could reduce variability in program quality and compliance, supporting equity in access to evidence-based treatment across regions—particularly beneficial in underserved rural or low-income communities.
HealthcarePeopleRef: Sec. 1(2)(b), (3)
Potential Concerns (1)
Opioid treatment programs—especially small, nonprofit, or publicly funded clinics—will face new financial burdens from mandatory accreditation fees, which must be set at cost-recovery levels; this could strain resources for programs serving low-income or uninsured patients, potentially reducing service capacity or leading to closures.
HealthcarePeopleRef: Sec. 1(3)
Who Is Most Affected
Opioid treatment programs—especially small, nonprofit, or publicly funded clinics—will bear direct costs for accreditation fees. While improved oversight may enhance credibility and funding eligibility, many programs operate on thin margins and may reduce service hours or close if fees are high relative to revenue.
Residents receiving medication-assisted treatment (MAT) may benefit from more consistent quality standards and potentially expanded access if accreditation improves program viability. However, if clinics close or reduce hours due to fee burdens, access could decline—especially for low-income, unhoused, or rural patients.
The Department of Health gains new authority and funding flexibility, but must invest staff time and resources to implement and enforce accreditation. This could strain existing capacity unless offset by settlement funds or fee revenue, and may divert attention from other public health priorities.
State and local governments benefit from reduced liability risk and improved public health outcomes if accreditation improves treatment outcomes and reduces overdose deaths—potentially lowering emergency response, criminal justice, and social service costs.
While not direct payers, insurers and Medicaid may benefit from more standardized, high-quality providers—potentially reducing utilization of high-cost emergency or inpatient care. However, they bear no direct cost and gain little financially relative to the public health benefit.